Archives of Industrial Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Opinion Article - Archives of Industrial Biotechnology (2024) Volume 8, Issue 4

Proteomics in drug discovery: Challenges and opportunities

Kamil Verma*

School of Biological and Environmental Sciences, Shoolini University of Biotechnology and Management Sciences, Himachal Pradesh, India

*Corresponding Author:
Kamil Verma
School of Biological and Environmental Sciences
Shoolini University of Biotechnology and Management Sciences
Himachal Pradesh, India
E-mail:kamil83@gmail.com

Received: 24-Jul-2024, Manuscript No. AAAIB-24-144205; Editor assigned: 26-Jul-2024, PreQC No. AAAIB-24-144205 (PQ); Reviewed: 07-Aug-2024, QC No. AAAIB-24-144205; Revised: 19-Aug-2024, Manuscript No. AAAIB-24-144205 (R); Published: 23-Aug-2024, DOI: 10.35841/aaaib- 8.4.221

Citation: Verma K. Proteomics in drug discovery: Challenges and opportunities. Arch Ind Biot. 2024; 8(4):221

Visit for more related articles at Archives of Industrial Biotechnology

Proteomics, the large-scale study of proteins, has emerged as a powerful tool in drug discovery. By providing a comprehensive understanding of protein expression, function, and interactions, proteomics offers valuable insights that can enhance the development of new therapeutics. However, the integration of proteomics into drug discovery is not without challenges. Proteomics enables the identification of protein biomarkers that are indicative of disease states or therapeutic responses. These biomarkers can be used for early diagnosis, patient stratification, and monitoring treatment efficacy, ultimately leading to more personalized and effective therapies. By analyzing the proteome of diseased versus healthy tissues, researchers can identify potential drug targets. Proteomics can reveal proteins that are differentially expressed or modified in disease, providing a basis for the development of targeted therapies. Additionally, proteomics can validate the relevance of these targets by elucidating their biological functions and interactions [1], [2]

Proteomics provides detailed information on protein pathways and networks, helping to elucidate the mechanisms underlying disease. This knowledge can guide the design of drugs that modulate specific proteins or pathways, leading to more precise and effective treatments. Proteomics can be used to study the effects of drugs on the proteome, revealing their mechanisms of action and potential off-target effects. This information is crucial for optimizing drug efficacy and safety, as well as for understanding side effects and developing strategies to mitigate them. Proteomics plays a key role in the development of biopharmaceuticals, such as monoclonal antibodies and protein therapeutics. It aids in the characterization of these complex molecules, ensuring their quality, stability, and efficacy [3].

Despite advances in proteomic technologies, challenges remain in achieving comprehensive proteome coverage, especially for low-abundance proteins. Sensitivity, reproducibility, and throughput of proteomic analyses need continuous improvement to meet the demands of drug discovery. Proteomic data is highly complex and voluminous, posing challenges in data analysis and interpretation. Integrating proteomic data with other omics data and translating it into actionable biological insights require sophisticated bioinformatics tools and expertise [4], [5]

Biological variability, such as differences in tissue types, disease stages, and patient populations, can complicate proteomic analyses. Standardizing sample collection, processing, and analysis protocols is essential to obtain reliable and reproducible results. High costs associated with proteomic technologies and the need for specialized equipment and expertise can limit their accessibility, particularly for smaller research institutions and companies. Reducing costs and increasing the availability of proteomic platforms is crucial for wider adoption in drug discovery. Translating proteomic discoveries into clinical applications involves significant hurdles, including regulatory approval, scalability, and clinical validation. Bridging the gap between proteomic research and clinical practice requires interdisciplinary collaboration and substantial investment. Continued innovation in proteomic technologies, such as mass spectrometry, protein microarrays, and single-cell proteomics, will enhance sensitivity, throughput, and accuracy. Emerging techniques, such as nanoproteomics and spatial proteomics, offer exciting possibilities for probing the proteome at unprecedented levels of detail [6], [7]

Combining proteomics with genomics, transcriptomics, metabolomics, and other omics data will provide a holistic view of biological systems. Integrated multi-omics approaches can uncover new drug targets, biomarkers, and therapeutic strategies. Leveraging AI and machine learning algorithms can significantly improve the analysis and interpretation of proteomic data. These tools can identify patterns, predict protein functions, and generate hypotheses, accelerating the drug discovery process. Collaboration between academia, industry, and regulatory agencies is essential to overcome the challenges and translate proteomic discoveries into clinical applications. Public-private partnerships and consortiums can facilitate resource sharing, standardization, and validation efforts [8], [9]

Proteomics holds immense promise for transforming drug discovery by providing deep insights into protein function, disease mechanisms, and therapeutic targets. While challenges remain, ongoing advancements in technology, data analysis, and collaborative efforts are paving the way for proteomics to become an integral part of the drug discovery pipeline. By harnessing the power of proteomics, researchers can develop more effective and personalized treatments, ultimately improving patient outcomes and advancing the field of medicine [10].

References

  1. Meissner F, Geddes-McAlister J, Mann M, et al. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat Rev Drug Discov. 2022;21(9):637-54.

    2. Indexed at, Google Scholar, Cross Ref

  2. Gupta R, Srivastava D, Sahu M, et al. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021;25:1315-60.

    3. Indexed at, Google Scholar, Cross Ref

  3. Aggarwal S, Karmakar A, Krishnakumar S, et al. Advances in drug discovery based on genomics, proteomics and bioinformatics in malaria. Curr Top Med Chem. 2023;23(7):551-78.

    4. Indexed at, Google Scholar, Cross Ref

  4. Prasad B. Quantitative proteomics in drug discovery and development. Drug Discov Today Technol. 2021;40:27-8.

    5. Indexed at, Google Scholar, Cross Ref

  5. Bhatia HS, Brunner AD, Öztürk F, et al. Spatial proteomics in three-dimensional intact specimens. Cell. 2022;185(26):5040-58.

    6. Indexed at, Google Scholar, Cross Ref

  6. Mund A, Brunner AD, Mann M. Unbiased spatial proteomics with single-cell resolution in tissues. Mol Cell. 2022;82(12):2335-49.

    7. Indexed at, Google Scholar, Cross Ref

  7. Li K, Du Y, Li L, et al. Bioinformatics approaches for anti-cancer drug discovery. Curr Drug Targets. 2020;21(1):3-17.

    8. Indexed at, Google Scholar, Cross Ref

  8. Benns HJ, Wincott CJ, Tate EW, et al. Activity-and reactivity-based proteomics: Recent technological advances and applications in drug discovery. Curr Opin Chem Biol. 2021;60:20-9.

    9. Indexed at, Google Scholar, Cross Ref

  9. Cui M, Cheng C, Zhang L. High-throughput proteomics: a methodological mini-review. Lab Invest. 2022;102(11):1170-81.

    10. Indexed at, Google Scholar, Cross Ref

  10. Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53(12):1712-21.

    11. Indexed at, Google Scholar, Cross Ref

Get the App